Title:
COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES
Document Type and Number:
WIPO Patent Application WO/2010/105008
Kind Code:
A3
Abstract:
Combinations of PDK inhibitor compounds having Formula (I) and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Inventors:
EBENS ALLEN J JR (US)
FRIEDMAN LORI (US)
FRIEDMAN LORI (US)
Application Number:
PCT/US2010/026903
Publication Date:
November 25, 2010
Filing Date:
March 11, 2010
Export Citation:
Assignee:
GENENTECH INC (US)
EBENS ALLEN J JR (US)
FRIEDMAN LORI (US)
EBENS ALLEN J JR (US)
FRIEDMAN LORI (US)
International Classes:
A61K31/519; A61P35/00
Domestic Patent References:
| WO2007129161A2 | 2007-11-15 | |||
| WO2007127175A2 | 2007-11-08 | |||
| WO2009036082A2 | 2009-03-19 | |||
| WO2009117277A2 | 2009-09-24 | |||
| WO2010012965A2 | 2010-02-04 |
Foreign References:
| JP2009534461A | 2009-09-24 |
Other References:
SAMPATH D ET AL: "220 POSTER Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB LNKD- DOI:10.1016/S1359-6349(08)72152-9, vol. 6, no. 12, 1 October 2008 (2008-10-01), pages 69 - 70, XP025534282, ISSN: 1359-6349, [retrieved on 20081001]
BUITENHUIS MIRANDA ET AL: "Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis", BLOOD, vol. 111, no. 1, January 2008 (2008-01-01), pages 112 - 121, XP002592635
FOLKES ADRIAN J ET AL: "The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-pipera zin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 18, September 2008 (2008-09-01), pages 5522 - 5532, XP002592636, ISSN: 0022-2623
REWCASTLE GORDON W ET AL: "Inhibitors of phosphatidylinositol 3-kinases: the next wave of anti-cancer drugs?", CHEMISTRY IN NEW ZEALAND, XX, NZ, vol. 73, no. 1, 1 January 2009 (2009-01-01), pages 9 - 11, XP009121915, ISSN: 0110-5566
JUNTTILA TEEMU T ET AL: "Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.", CANCER CELL 5 MAY 2009 LNKD- PUBMED:19411071, vol. 15, no. 5, 5 May 2009 (2009-05-05), pages 429 - 440, XP002592637, ISSN: 1878-3686
SOS MARTIN L ET AL: "Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 27 OCT 2009 LNKD- PUBMED:19805051, vol. 106, no. 43, 27 October 2009 (2009-10-27), pages 18351 - 18356, XP002592638, ISSN: 1091-6490
BUITENHUIS MIRANDA ET AL: "Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis", BLOOD, vol. 111, no. 1, January 2008 (2008-01-01), pages 112 - 121, XP002592635
FOLKES ADRIAN J ET AL: "The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-pipera zin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 18, September 2008 (2008-09-01), pages 5522 - 5532, XP002592636, ISSN: 0022-2623
REWCASTLE GORDON W ET AL: "Inhibitors of phosphatidylinositol 3-kinases: the next wave of anti-cancer drugs?", CHEMISTRY IN NEW ZEALAND, XX, NZ, vol. 73, no. 1, 1 January 2009 (2009-01-01), pages 9 - 11, XP009121915, ISSN: 0110-5566
JUNTTILA TEEMU T ET AL: "Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.", CANCER CELL 5 MAY 2009 LNKD- PUBMED:19411071, vol. 15, no. 5, 5 May 2009 (2009-05-05), pages 429 - 440, XP002592637, ISSN: 1878-3686
SOS MARTIN L ET AL: "Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 27 OCT 2009 LNKD- PUBMED:19805051, vol. 106, no. 43, 27 October 2009 (2009-10-27), pages 18351 - 18356, XP002592638, ISSN: 1091-6490
Attorney, Agent or Firm:
ANDRUS, Alex et al. (Inc.1 DNA Way, MS-4, South San Francisco CA, US)
Download PDF:
Previous Patent: POWDER METAL SCROLLS AND SINTER-BRAZING METHODS FOR MAKING THE SAME
Next Patent: PROCESS FOR MAKING AN EMBOSSED WEB
Next Patent: PROCESS FOR MAKING AN EMBOSSED WEB